Intellia initiated a rolling Biologics License Application for lonvo-z after positive Phase 3 results, aiming for FDA approval and a potential U.S. launch in the first half of 2027.
The Phase 3 HAELO trial showed lonvo-z reduced HAE attacks by 87% versus placebo, with 62% of patients attack-free and favorable safety over six months.
If approved, lonvo-z would become the world’s first in vivo CRISPR-based gene editing therapy, offering a one-time treatment for hereditary angioedema, a rare and potentially life-threatening genetic disorder.
Beyond rare disorders, could this in-body gene editing technology one day tackle more common conditions?
Will this one-time treatment model, offering a potential cure, disrupt the entire pharmaceutical industry?
As gene editing 'cures' become reality, how will healthcare systems handle their multi-million dollar price tags?
With DNA permanently altered, what are the lifelong health risks, and how will patients be monitored?
How can we be sure editing one gene won't accidentally break another, causing future health problems?